Stay updated with breaking news from 46433010. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AtonRa Partners reduced its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 21.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,875 shares of the company’s stock after selling 3,753 shares during the period. AtonRa Partners’ holdings in […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) traded down 3.9% during trading on Tuesday . The company traded as low as $36.23 and last traded at $36.31. 249,701 shares were traded during trading, a decline of 74% from the average session volume of 942,465 shares. The stock had previously closed at $37.78. Wall Street Analyst […]
Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) had its target price boosted by Morgan Stanley from $40.00 to $42.00 in a report released on Tuesday morning, Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock. A number of other brokerages also recently weighed in on IONS. Needham & Company LLC reiterated a […]
Bard Financial Services Inc. decreased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 38.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 53,925 shares of the company’s stock after selling 33,970 shares during the period. Bard Financial Services Inc.’s holdings […]
Sanford C. Bernstein started coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) in a research note issued to investors on Tuesday, The Fly reports. The firm issued an underperform rating and a $31.00 price target on the stock. A number of other brokerages have also weighed in on IONS. SVB Leerink reduced their […]